GlassScriptPhysician profile
Lauryn Mclaughlin
NPI 1073235057
$3,857.84
in general payments reported to CMS, 2019-2025
29 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.27 · 2023: $1,634 · 2024: $1,335 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,528 · Education: $246 · Consulting Fee: $37.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,528.13 |
| Education | $246.02 |
| Consulting Fee | $37.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.20 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $566.47 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $453.54 | 2023-2025 | Hyqvia, Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $451.79 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $272.50 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $239.50 | 2023-2025 | Tezspire |
| Kaleo, INC. | $135.40 | 2023-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $127.87 | 2023-2025 | |
| Csl Behring | $121.99 | 2022-2025 | Haegarda, Hizentra, Kcentra |
| Grifols USA, LLC | $103.21 | 2023-2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Hospira, INC. | $88.24 | 2024 | |
| Pfizer INC. | $81.33 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $67.60 | 2024-2025 | Ryaltris |
| Genentech USA, INC. | $49.00 | 2023 | Xolair |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $42.69 | 2023 | |
| Adma Biomanufacturing LLC | $37.42 | 2023 | |
| Azurity Pharmaceuticals, INC. | $37.12 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $29.29 | 2025 | Dawnzera |
| Leo Pharma INC. | $23.50 | 2023 | Adbry |
| Seqirus USA INC | $22.23 | 2025 | Flucelvax |
| Biocryst US Sales Co., LLC | $22.16 | 2023 | Orladeyo |
| Blueprint Medicines Corporation | $21.64 | 2023 | Ayvakit |
| Gc Biopharma USA, INC. | $21.16 | 2025 | Alyglo |
| Cycle Pharmaceuticals INC | $19.56 | 2025 | Sajazir |
| Pharming Healthcare, INC. | $19.42 | 2024 | Ruconest |
| Merck Sharp & Dohme LLC | $16.17 | 2023 | |
| Octapharma USA, INC. | $16.14 | 2023 | Octagam Immune Globulin (Human) |
| Greer Laboratories, INC. | $14.75 | 2025 | Oralair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauryn Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.